Technical Analysis for LCTX - Lineage Cell Therapeutics, Inc.

Grade Last Price % Change Price Change
C 2.355 2.84% 0.07
LCTX closed down 6.53 percent on Thursday, February 25, 2021, on approximately normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Flat Down
Historical LCTX trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 2.84%
Wide Bands Range Expansion 2.84%
Down 3 Days in a Row Weakness 2.84%
Down 4 Days in a Row Weakness 2.84%
Down 5 Days in a Row Weakness 2.84%
20 DMA Resistance Bearish -3.88%
Wide Bands Range Expansion -3.88%
Down 3 Days in a Row Weakness -3.88%
Down 4 Days in a Row Weakness -3.88%
Down 5 Days in a Row Weakness -3.88%
Older End-of-Day Signals for LCTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 5% about 1 hour ago
50 DMA Support about 2 hours ago
Down 5% about 2 hours ago
Down 3% about 3 hours ago
Down 2 % about 3 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Lineage Cell Therapeutics, Inc. Description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Clinical Development Immunotherapy Bone Cancer Immunotherapy Stem Cells Small Cell Lung Cancer Non Small Cell Lung Cancer Macular Degeneration Drug Delivery Related Macular Degeneration Degenerative Disease Osteoarthritis Cell Therapy Degenerative Diseases Retina Injuries Human Disease Aesthetics Spinal Cord Pivotal Progenitor Cell Starch Bone Grafting Helium Dendritic Cell Stem Cell Therapy EMV Biotime Dry Age Related Macular Degeneration Treatment Of Degenerative Diseases

Is LCTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.13
52 Week Low 0.5801
Average Volume 1,919,035
200-Day Moving Average 1.35
50-Day Moving Average 2.29
20-Day Moving Average 2.65
10-Day Moving Average 2.77
Average True Range 0.24
ADX 19.66
+DI 16.93
-DI 35.81
Chandelier Exit (Long, 3 ATRs ) 2.40
Chandelier Exit (Short, 3 ATRs ) 2.84
Upper Bollinger Band 3.21
Lower Bollinger Band 2.09
Percent B (%b) 0.18
BandWidth 42.42
MACD Line 0.08
MACD Signal Line 0.17
MACD Histogram -0.0837
Fundamentals Value
Market Cap 343.48 Million
Num Shares 150 Million
EPS 0.23
Price-to-Earnings (P/E) Ratio 9.87
Price-to-Sales 85.10
Price-to-Book 2.53
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.60
Resistance 3 (R3) 2.62 2.54 2.55
Resistance 2 (R2) 2.54 2.46 2.53 2.53
Resistance 1 (R1) 2.42 2.41 2.37 2.39 2.52
Pivot Point 2.33 2.33 2.31 2.32 2.33
Support 1 (S1) 2.21 2.25 2.17 2.19 2.06
Support 2 (S2) 2.12 2.20 2.11 2.05
Support 3 (S3) 2.00 2.12 2.03
Support 4 (S4) 1.98